Intelligence Β· Patent portfolio
Vertex Pharmaceuticals (Australia) Patents
Full USPTO pharma patent portfolio for Vertex Pharmaceuticals (Australia) β grant dates, expiration, and drug cross-links.
- Patents
- 991
- Expiring β€24m
- 63
Quick answer
Vertex Pharmaceuticals (Australia) has 991 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 63 expire within 24 months β use filters for patent-cliff planning.
-
US 7365072
Inhibitors of p38
granted -
US 7361665
Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
granted -
US 7358273
Inhibitors of caspases
granted -
US 7358258
Prodrugs of an ERK protein kinase inhibitor
granted -
US 7354939
Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto
granted -
US 7354919
Isoxazole compositions useful as inhibitors of ERK
granted -
US 7351702
Caspase inhibitors and uses thereof
granted -
US 7348335
Compositions useful as inhibitors of JAK and other protein kinases
granted -
US 7345054
Heterocyclic inhibitors of ERK2 and uses thereof
granted -
US 7329652
Diaminotriazole compounds useful as protein kinase inhibitors
granted -
US 7329681
Inhibitors of IMPDH enzyme
granted -
US 7323616
Genetically altered mice deficient in functional caspase-9
granted -
US 7321063
Sulfonamide inhibitors of aspartyl protease
granted -
US 7314885
Pyrrole compounds useful as kinase inhibitors
granted -
US 7312227
Compositions useful as inhibitors of JAK and other protein kinases
granted -
US 7309716
Benzimidazoles useful as modulators of ion channels
granted -
US 7304061
Heterocyclic inhibitors of ERK2 and uses thereof
granted -
US 7304071
Protein kinase inhibitors and uses thereof
granted -
US 7288624
Inhibitors of interleukin-1Ξ² converting enzyme
granted -
US 7279469
Diaminotriazoles useful as inhibitors of protein kinases
granted -
US 7279476
Pyrazole-derived kinase inhibitors and uses thereof
granted -
US 7276502
Thiazoles useful as inhibitors of protein kinases
granted -
US 7273885
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
granted -
US 7271179
Inhibitors of JAK protein kinase
granted -
US 7271181
Inhibitors of p38
granted -
US 7268136
Compositions useful as inhibitors of protein kinases
granted -
US 7259161
Compositions useful as inhibitors of JAK and other protein kinases
granted -
US 7256190
Thiazole compounds useful as inhibitors of protein kinase
granted -
US 7253187
Heterocyclic inhibitors of ERK2 and uses thereof
granted -
US 7250520
Processes for preparing pyrroles
granted -
US 7244735
Heterocyclic protein kinase inhibitors and uses thereof
granted -
US 7241796
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
granted -
US 7226920
Aminotriazole compounds useful as inhibitors of protein kinases
granted -
US 7216041
Methods of using the structure coordinates of molecules comprising an IMPDH-like binding pocket
granted -
US 7208600
Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases
granted -
US 7205305
Inhibitors of p38
granted -
US 7205327
Imidazole and benzimidazole caspase inhibitors and uses thereof
granted -
US 7186737
Inhibitors of p38
granted -
US 7183307
Pyrazole-derived kinase inhibitors and uses thereof
granted -
US 7179826
Compositions useful as inhibitors of protein kinases
granted -
US 7169800
Imidazole compositions useful as inhibitors of protein kinases
granted -
US 7169779
Inhibitors of p38
granted -
US 7169798
Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases
granted -
US 7157476
Aminofurazan compounds useful as protein kinase inhibitors
granted -
US 7151101
Inhibitors of p38
granted -
US 7122552
Inhibitors of JAK and CDK2 protein kinases
granted -
US 7115746
Processes for the facile synthesis of diaryl amines and analogues thereof
granted -
US 7115637
Inhibitors of p38
granted
Frequently asked questions
How many patents does Vertex Pharmaceuticals (Australia) have?
991 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Vertex Pharmaceuticals (Australia) patents expire?
63 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory